Cyfuse BiomedicalCyfuse Biomedical K.K.4892東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP
Cyfuse Biomedical brought in ¥61.1M in revenue.
It lost about ¥1141 for every ¥100 of sales at the operating level.
Revenue changed -83.7% from the prior year.
FY ending Dec 2022 → FY ending Dec 2023
FY ending Dec 2022 → FY ending Dec 2023
For every ¥100 Cyfuse Biomedical sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
EDINET (FSA Japan)
有価証券報告書-第16期(2025/01/01-2025/12/31)
EDINET (FSA Japan)
有価証券報告書-第15期(2024/01/01-2024/12/31)
EDINET (FSA Japan)
有価証券報告書-第14期(2023/01/01-2023/12/31)
EDINET (FSA Japan)
有価証券報告書-第13期(2022/01/01-2022/12/31)
Extracted from XBRL: 39 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.